SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 69,374 shares, an increase of 471.9% from the October 15th total of 12,131 shares. Based on an average daily trading volume, of 4,376,407 shares, the days-to-cover ratio is currently 0.0 days. Currently, 12.5% of the company’s shares are sold short.
SciSparc Stock Down 2.9%
Shares of NASDAQ SPRC traded down $0.01 during trading on Friday, hitting $0.34. The company had a trading volume of 31,595 shares, compared to its average volume of 800,760. SciSparc has a fifty-two week low of $0.35 and a fifty-two week high of $29.88. The stock has a fifty day simple moving average of $3.09 and a two-hundred day simple moving average of $5.21.
SciSparc (NASDAQ:SPRC – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($4.85) earnings per share (EPS) for the quarter. The company had revenue of $0.14 million for the quarter.
Analysts Set New Price Targets
SPRC has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Friday, August 21st. Wall Street Zen upgraded shares of SciSparc to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Stock Report on SPRC
About SciSparc
SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based clinical-stage specialty pharmaceutical company focused on developing therapies based on cannabinoid molecules. The company’s research is aimed primarily at central nervous system disorders and other conditions for which existing treatment options may be limited. SciSparc’s pipeline has included investigational products such as SCI-110, a cannabinoid-based combination therapy being studied for conditions including Tourette syndrome and obstructive sleep apnea, as well as programs addressing Alzheimer’s disease agitation and pain.
Featured Articles
- Five stocks we like better than SciSparc
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
